Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Braidwell LP

Braidwell LP raised its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 71.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 884,306 shares of the company’s stock after purchasing an additional 367,663 shares during the period. Braidwell LP owned 2.39% of Celcuity worth $13,185,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in shares of Celcuity in the 3rd quarter worth $33,000. Prospera Private Wealth LLC purchased a new stake in shares of Celcuity during the 3rd quarter worth about $35,000. Values First Advisors Inc. acquired a new stake in Celcuity during the 3rd quarter worth approximately $86,000. Quest Partners LLC lifted its position in Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Celcuity during the third quarter worth approximately $119,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

Shares of CELC stock opened at $12.85 on Friday. Celcuity Inc. has a one year low of $11.51 and a one year high of $22.19. The company’s 50-day simple moving average is $14.74 and its 200-day simple moving average is $15.77. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CELC shares. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Lifesci Capital began coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th. Finally, Stifel Nicolaus raised their target price on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Celcuity currently has an average rating of “Buy” and an average target price of $29.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.